Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00399789 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by AEterna Zentaris.
- Completed
- Registry status
- Phase 1
- Development phase
- 121
- Enrollment target
NCT00399789 is a Phase 1 study that has completed, run by AEterna Zentaris. The registered enrollment target is 121 participants.
The verdict
NCT00399789, a Phase 1 study, has completed, sponsored by AEterna Zentaris.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 121 participants
- Enrollment target
Study Summary
This is a study of the drug perifosine that consists of 2 parts. The first part of this study was designed to determine the highest dose of perifosine that can be administered to people every week without severe or prolonged nausea, vomiting and diarrhea. This study started with patients taking 900 mg/week and went up to 1800 mg/week. Part I of this study is completed. The MTD had been determined and incorporated in Part II. The goals in Part II are to: 1. Compare the gastrointestinal toxicity of 3 different dose-schedules and 2. Obtain preliminary information on the response rate of perifosine in non-small cell lung cancer.
Interventions
- DRUG Perifosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2004-09 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00399789
The ClinicalTrials.gov registry entry for NCT00399789 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AEterna Zentaris, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Perifosine is the first listed.
NCT00399789 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00399789 about?
NCT00399789 is a clinical study titled "A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer". This is a study of the drug perifosine that consists of 2 parts. The first part of this study was designed to determine the highest dose of perifosine that can be administered to people every week without severe or prolonged nausea, vomiting and diarrhea. This study started with patients taking 900 ...
What is the current status of trial NCT00399789?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 121 participants. The study started on 2004-09. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00399789?
The interventions under investigation include: Perifosine (DRUG).
Who is sponsoring clinical trial NCT00399789?
This trial is sponsored by AEterna Zentaris, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.